USPTO serial 79331946
CRESCENDO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 6, 2022
- Examiner
- RILEY, KATHERINE M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CRESCENDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew L. Frisbee
Matthew L. Frisbee Leason Ellis LLPOne North Lexington Ave., Suite 1200White Plains, NY 10601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products; chemicals used in industry and science | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto; pharmaceutical preparations for use in oncology | ACTIVE | — |
| 031 | Live animals; live mice | ACTIVE | — |
| 040 | Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; oncological research; engineering of antibodies and antibody fragments; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services | ACTIVE | — |
| 045 | Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 031
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named CRESCENDO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 3, 2025 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 8, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Oct 27, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 19, 2023 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Apr 19, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 29, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 28, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 6, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 6, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 6, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 27, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 20, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 20, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 7, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 7, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 31, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 11, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 11, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 16, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 16, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 24, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 23, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 2, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 29, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 27, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |